PIK3CA and colorectal carcinoma: Molecular changes such as the presence of 20q amplification combined with the absence of mutations in the PI(3)K signalling pathway and low CIMP in a CRC primary tumour might become a reason to perform tailored follow-up and eventually targeted therapy.